A quick peek into the report
Table of Contents
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.2 Industry Outlook
1.2.1 Market Overview
1.2.1.1 Timeline of Emerging Technologies for Infectious Disease Diagnostics
1.2.1.2 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
1.2.1.3 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
1.2.1.4 Current Market Landscape of Emerging Infectious Disease Diagnostics
1.2.1.5 Future Potential
1.2.1.5.1 CRISPR
1.2.1.5.2 NGS
1.2.1.5.3 INAAT
1.2.1.5.4 Digital PCR (dPCR)
1.2.2 Patent Analysis
1.2.2.1 By Year
1.2.2.2 By Country/Organization
1.2.3 Pipeline Analysis
1.2.4 Impact of COVID-19 on Infectious Disease Diagnostics
1.2.4.1 Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
1.2.5 Supply Chain Analysis
1.3 Market Dynamics
1.3.1 Impact Analysis
1.3.2 Drivers
1.3.2.1 Economic Burden of Infectious Diseases
1.3.2.2 Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
1.3.2.3 Increasing Demand for Point-of-Care (POC) and Syndromic Testing
1.3.2.4 Technological Advancements in Molecular Diagnostics
1.3.2.4.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
1.3.2.4.2 Digital PCR
1.3.2.4.3 CRISPR Technologies
1.3.3 Restraints
1.3.3.1 Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
1.3.3.2 Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
1.3.3.3 Lack of an Established Framework for NGS-based Tests for Infectious Diseases
1.3.4 Opportunities
1.3.4.1 Potential of Molecular Diagnostic Tests in Low-Resource Settings
1.3.4.2 Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance
2.1 Overview
2.2 Laboratory Testing
2.3 Point-of-Care Testing
3.1 Overview
3.2 Polymerase Chain Reaction (PCR)
3.2.1 Reverse Transcription PCR (RT-PCR)
3.2.2 Digital PCR
3.3 Immunodiagnostics
3.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
3.5 Next-Generation Sequencing (NGS)
3.6 Other Technologies
4.1 Overview
4.2 Bacterial
4.3 Viral
4.4 Fungal
4.5 Other Infections
5.1 Overview
5.2 Respiratory Infections
5.3 Gastrointestinal Infections
5.4 Sexually Transmitted Infections (STIs)
5.5 Other Infections
6.1 Overview
6.2 Hospitals and Clinics
6.3 Diagnostic Laboratories
6.4 Other End Users
7.1 North America Emerging Infectious Disease Diagnostics Market
7.1.1 Regulatory Framework
7.1.2 Market Dynamics
7.1.2.1 Impact Analysis
7.1.3 Market Sizing and Forecast
7.1.3.1 North America Emerging Infectious Disease Diagnostics Market (by Application)
7.1.3.2 North America Emerging Infectious Disease Diagnostics Market (by Technology)
7.1.3.3 North America Emerging Infectious Disease Diagnostics Market (by Type of Infection)
7.1.3.4 North America Emerging Infectious Disease Diagnostics Market (by Disease Type)
7.1.3.5 North America Emerging Infectious Disease Diagnostics Market (by End User)
7.1.3.6 North America Emerging Infectious Disease Diagnostics Market (by Country)
7.1.3.6.1 U.S.
7.1.3.6.1.1 Market Dynamics
7.1.3.6.1.2 Market Size and Forecast
7.1.3.6.1.2.1 U.S. Emerging Infectious Disease Diagnostics Market (by End User)
7.1.3.6.2 Canada
7.1.3.6.2.1 Market Dynamics
7.1.3.6.2.2 Market Size and Forecast
7.1.3.6.2.2.1 Canada Emerging Infectious Disease Diagnostics Market (by End User)
7.2 Europe Emerging Infectious Disease Diagnostics Market
7.2.1 Regulatory Framework
7.2.2 Market Dynamics
7.2.2.1 Impact Analysis
7.2.3 Market Sizing and Forecast
7.2.3.1 Europe Emerging Infectious Disease Diagnostics Market (by Application)
7.2.3.2 Europe Emerging Infectious Disease Diagnostics Market (by Technology)
7.2.3.3 Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection)
7.2.3.4 Europe Emerging Infectious Disease Diagnostics Market (by Disease Type)
7.2.3.5 Europe Emerging Infectious Disease Diagnostics Market (by End User)
7.2.3.5.1 Germany
7.2.3.5.1.1 Market Dynamics
7.2.3.5.1.2 Market Size and Forecast
7.2.3.5.1.2.1 Germany Emerging Infectious Disease Diagnostics Market (by End User)
7.2.3.5.2 U.K.
7.2.3.5.2.1 Market Dynamics
7.2.3.5.2.2 Market Size and Forecast
7.2.3.5.2.2.1 U.K. Emerging Infectious Disease Diagnostics Market (by End User)
7.2.3.5.3 France
7.2.3.5.3.1 Market Dynamics
7.2.3.5.3.2 Market Size and Forecast
7.2.3.5.3.2.1 France Emerging Infectious Disease Diagnostics Market (by End User)
7.2.3.5.4 Italy
7.2.3.5.4.1 Market Dynamics
7.2.3.5.4.2 Market Size and Forecast
7.2.3.5.4.2.1 Italy Emerging Infectious Disease Diagnostics Market (by End User)
7.2.3.5.5 Spain
7.2.3.5.5.1 Market Dynamics
7.2.3.5.5.2 Market Size and Forecast
7.2.3.5.5.2.1 Spain Emerging Infectious Disease Diagnostics Market (by End User)
7.2.3.5.6 Rest-of-Europe
7.2.3.5.6.1 Market Dynamics
7.2.3.5.6.2 Market Size and Forecast
7.2.3.5.6.2.1 Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User)
7.3 Asia-Pacific Emerging Infectious Disease Diagnostics Market
7.3.1 Regulatory Framework
7.3.2 Market Dynamics
7.3.2.1 Impact Analysis
7.3.3 Market Size and Forecast
7.3.3.1 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Application)
7.3.3.2 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Technology)
7.3.3.3 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Type of Infection)
7.3.3.4 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Disease Type)
7.3.3.5 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User)
7.3.3.6 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Country)
7.3.3.6.1 Japan
7.3.3.6.1.1 Market Dynamics
7.3.3.6.1.2 Market Size and Forecast
7.3.3.6.1.2.1 Japan Emerging Infectious Disease Diagnostics Market (by End User)
7.3.3.6.2 China
7.3.3.6.2.1 Market Dynamics
7.3.3.6.2.2 Market Size and Forecast
7.3.3.6.2.2.1 China Emerging Infectious Disease Diagnostics Market (by End User)
7.3.3.6.3 Australia
7.3.3.6.3.1 Market Dynamics
7.3.3.6.3.2 Market Size and Forecast
7.3.3.6.3.2.1 Australia Emerging Infectious Disease Diagnostics Market (by End User)
7.3.3.6.4 South Korea
7.3.3.6.4.1 Market Dynamics
7.3.3.6.4.2 Market Size and Forecast
7.3.3.6.4.2.1 South Korea Emerging Infectious Disease Diagnostics Market (by End User)
7.3.3.6.5 India
7.3.3.6.5.1 Market Dynamics
7.3.3.6.5.2 Market Size and Forecast
7.3.3.6.5.2.1 India Emerging Infectious Disease Diagnostics Market (by End User)
7.3.3.6.6 Rest-of-Asia-Pacific
7.3.3.6.6.1 Market Dynamics
7.3.3.6.6.2 Market Size and Forecast
7.3.3.6.6.2.1 Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User)
7.4 Latin America Emerging Infectious Disease Diagnostics Market
7.4.1 Regulatory Framework
7.4.2 Market Dynamics
7.4.2.1 Impact Analysis
7.4.3 Market Size and Forecast
7.4.3.1 Latin America Emerging Infectious Disease Diagnostics Market (by Application)
7.4.3.2 Latin America Emerging Infectious Disease Diagnostics Market (by Technology)
7.4.3.3 Latin America Emerging Infectious Disease Diagnostics Market (by Type of Infection)
7.4.3.4 Latin America Emerging Infectious Disease Diagnostics Market (by Disease Type)
7.4.3.5 Latin America Emerging Infectious Disease Diagnostics Market (by End User)
7.4.3.6 Latin America Emerging Infectious Disease Diagnostics Market (by Country)
7.4.3.6.1 Brazil
7.4.3.6.1.1 Market Dynamics
7.4.3.6.1.2 Market Size and Forecast
7.4.3.6.1.2.1 Brazil Emerging Infectious Disease Diagnostics Market (by End User)
7.4.3.6.2 Mexico
7.4.3.6.2.1 Market Dynamics
7.4.3.6.2.2 Market Size and Forecast
7.4.3.6.2.2.1 Mexico Emerging Infectious Disease Diagnostics Market (by End User)
7.4.3.6.3 Rest-of-Latin America
7.4.3.6.3.1 Market Dynamics
7.4.3.6.3.2 Market Size and Forecast
7.4.3.6.3.2.1 Rest-of-Latin America Emerging Infectious Disease Diagnostics Market (by End User)
7.5 Middle East and Africa Emerging Infectious Disease Diagnostics Market
7.5.1 Regulatory Framework
7.5.2 Market Dynamics
7.5.2.1 Impact Analysis
7.5.3 Market Size and Forecast
7.5.3.1 Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Application)
7.5.3.2 Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Technology)
7.5.3.3 Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Type of Infection)
7.5.3.4 Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Disease Type)
7.5.3.5 Middle East and Africa Emerging Infectious Disease Diagnostics Market (by End User)
7.5.3.6 Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Country)
7.5.3.6.1 U.A.E.
7.5.3.6.1.1 Market Dynamics
7.5.3.6.1.2 Market Size and Forecast
7.5.3.6.1.2.1 U.A.E. Emerging Infectious Disease Diagnostics Market (by End User)
7.5.3.6.2 K.S.A.
7.5.3.6.2.1 Market Dynamics
7.5.3.6.2.2 Market Size and Forecast
7.5.3.6.2.2.1 K.S.A. Emerging Infectious Disease Diagnostics Market (by End User)
7.5.3.6.3 Rest-of-Middle East and Africa
7.5.3.6.3.1 Market Dynamics
7.5.3.6.3.2 Market Size and Forecast
7.5.3.6.3.2.1 Rest-of-Middle East and Africa Emerging Infectious Disease Diagnostics Market (by End User)
8.1 Competitive Landscape
8.1.1 Overview
8.1.2 Corporate Strategies
8.1.2.1 Mergers and Acquisitions
8.1.2.2 Synergistic Activities
8.1.2.3 Business Expansions and Funding
8.1.3 Business Strategies
8.1.3.1 Product Launches/Upgradations/Approvals
8.2 Market Share Analysis
8.3 Emerging Infectious Disease Diagnostics Ecosystem Active Players
8.4 Company Profiles
8.4.1 Abbott Laboratories
8.4.1.1 Company Overview
8.4.1.2 Role of Abbott Laboratories in the Global Emerging Infectious Disease Diagnostics Market
8.4.1.3 Financials
8.4.1.4 Recent Developments
8.4.1.5 Analyst Perspective
8.4.2 Becton, Dickinson and Company
8.4.2.1 Company Overview
8.4.2.2 Role of Becton, Dickinson and Company in the Global Emerging Infectious Disease Diagnostics Market
8.4.2.3 Financials
8.4.2.4 Recent Developments
8.4.2.5 Analyst Perspective
8.4.3 bioMérieux S.A.
8.4.3.1 Company Overview
8.4.3.2 Role of bioMérieux S.A. in the Global Emerging Infectious Disease Diagnostics Market
8.4.3.3 Financials
8.4.3.1 Recent Developments
8.4.3.2 Analyst Perspective
8.4.4 Bio-Rad Laboratories, Inc.
8.4.4.1 Company Overview
8.4.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Emerging Infectious Disease Diagnostics Market
8.4.4.3 Financials
8.4.4.4 Recent Developments
8.4.4.5 Analyst Perspective
8.4.5 Co-Diagnostics, Inc.
8.4.5.1 Company Overview
8.4.5.2 Role of Co-Diagnostics, Inc. in the Global Emerging Infectious Disease Diagnostics Market
8.4.5.3 Recent Developments
8.4.5.4 Analyst Perspective
8.4.6 DANAHER CORPORATION
8.4.6.1 Company Overview
8.4.6.2 Role of DANAHER CORPORATION in the Global Emerging Infectious Disease Diagnostics Market
8.4.6.3 Financials
8.4.6.4 Recent Developments
8.4.6.5 Analyst Perspective
8.4.7 DiaSorin S.p.A.
8.4.7.1 Company Overview
8.4.7.2 Role of DiaSorin S.p.A. in the Global Emerging Infectious Disease Diagnostics Market
8.4.7.3 Financials
8.4.7.4 Recent Developments
8.4.7.5 Analyst Perspective
8.4.8 F. Hoffmann-La Roche Ltd
8.4.8.1 Company Overview
8.4.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Emerging Infectious Disease Diagnostics Market
8.4.8.3 Financials
8.4.8.4 Recent Developments
8.4.8.5 Analyst Perspective
8.4.9 Hologic, Inc.
8.4.9.1 Company Overview
8.4.9.2 Role of Hologic, Inc. in the Global Emerging Infectious Disease Diagnostics Market
8.4.9.3 Financials
8.4.9.4 Recent Developments
8.4.9.5 Analyst Perspective
8.4.10 QIAGEN N.V.
8.4.10.1 Company Overview
8.4.10.2 Role of QIAGEN N.V. in the Global Emerging Infectious Disease Diagnostics Market
8.4.10.3 Financials
8.4.10.4 Recent Developments
8.4.10.5 Analyst Perspective
8.4.11 QuidelOrtho Corporation
8.4.11.1 Company Overview
8.4.11.2 Role of QuidelOrtho Corporation in the Global Emerging Infectious Disease Diagnostics Market
8.4.11.3 Financials
8.4.11.4 Recent Developments
8.4.11.5 Analyst Perspective
8.4.12 T2 Biosystems, Inc.
8.4.12.1 Company Overview
8.4.12.2 Role of T2 Biosystems, Inc. in the Global Emerging Infectious Disease Diagnostics Market
8.4.12.3 Recent Developments
8.4.12.4 Analyst Perspective
8.4.13 Tecan Trading AG
8.4.13.1 Company Overview
8.4.13.2 Role of Tecan Trading AG in the Global Emerging Infectious Disease Diagnostics Market
8.4.13.3 Financials
8.4.13.4 Recent Developments
8.4.13.5 Analyst Perspective
8.4.14 Thermo Fisher Scientific Inc.
8.4.14.1 Company Overview
8.4.14.2 Role of Thermo Fisher Scientific Inc. in the Global Emerging Infectious Disease Diagnostics Market
8.4.14.3 Financials
8.4.14.4 Recent Developments
8.4.14.5 Analyst Perspective
8.4.15 Siemens Healthineers AG
8.4.15.1 Company Overview
8.4.15.2 Role of Siemens Healthineers AG in the Global Emerging Infectious Disease Diagnostics Market
8.4.15.3 Financials
8.4.15.4 Recent Developments
8.4.15.5 Analyst Perspective
8.5 Company Snapshots
8.5.1 CrisprBits
8.5.1.1 Company Overview
8.5.1.2 Role of CrisprBits in the Global Emerging Infectious Disease Diagnostics Market
8.5.1.3 Key Developments
8.5.2 Proof Diagnostics Inc.
8.5.2.1 Company Overview
8.5.2.2 Role of Proof Diagnostics Inc. in the Global Emerging Infectious Disease Diagnostics Market
8.5.2.3 Key Developments
8.5.3 Evvy
8.5.3.1 Company Overview
8.5.3.2 Role of Evvy in the Global Emerging Infectious Disease Diagnostics Market
8.5.3.3 Key Developments
8.5.4 Sherlock Biosciences
8.5.4.1 Company Overview
8.5.4.2 Role of Sherlock Biosciences in the Global Emerging Infectious Disease Diagnostics Market
8.5.4.3 Key Developments
8.5.5 BioExcel Diagnostics
8.5.5.1 Company Overview
8.5.5.2 Role of BioExcel Diagnostics in the Global Emerging Infectious Disease Diagnostics Market
8.5.5.3 Key Developments
8.5.6 En Carta Diagnostics
8.5.6.1 Company Overview
8.5.6.2 Role of En Carta Diagnostics in the Global Emerging Infectious Disease Diagnostics Market
Table 1: Some of the Key Developments By Companies Leveraging Emerging Technologies in Infectious Disease Diagnostics
Table 2: Key Product Offerings by Players in the Global Emerging Infectious Disease Diagnostics Market
Table 3: Key Questions Answered in the Report
Table 4: Some of the RT-LAMP Assays Developed during COVID-19
Table 5: Molecular Diagnostic Products for Infectious Diseases Under Development
Table 6: At-Home COVID-19 Kits Approved for Commercial Use by ICMR
Table 7: Disease Burden for Infectious Diseases (DALY), Global, Million, 2019
Table 8: Key Initiatives by Governments Globally
Table 9: Examples of International Research Consortiums for Managing Response to Infectious Diseases
Table 10: List of Infectious Disease Outbreaks (by Region and Year)
Table 11: North America Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 12: Europe Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 13: Asia-Pacific Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 14: Latin America Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 15: Middle East and Africa Emerging Infectious Disease Diagnostics Market, Impact Analysis
Table 16: Global Emerging Infectious Disease Diagnostics Market, Key Active Players
Figure 1: History of Infectious Disease Outbreaks Globally
Figure 2: Number of Infectious Disease Outbreaks per Year Reported by the WHO, Global Estimates
Figure 3: Global Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 4: Global Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 5: Global Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 6: Global Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 7: Share of Key Developments, January 2019-June 2023
Figure 8: Global Emerging Infectious Disease Diagnostics Market (by Region), $Billion, 2022 and 2033
Figure 9: Market Share Analysis for Global Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 10: Key Insights Validated from Primary Interviews
Figure 11: Global Emerging Infectious Disease Diagnostics Market Segmentation
Figure 12: Global Emerging Infectious Disease Diagnostics Market Research Methodology
Figure 13: Primary Research Methodology
Figure 14: Bottom-Up Approach (Segment-Wise Analysis)
Figure 15: Top-Down Approach (Segment-Wise Analysis)
Figure 16: Timeline of Emerging Technologies for Infectious Disease Diagnostics
Figure 17: Advantages of Emerging Infectious Disease Diagnostic Technologies
Figure 18: Limitations of Emerging Infectious Disease Diagnostic Technologies
Figure 19: Key Settings of POC Testing Deployment
Figure 20: Key Challenges Associated with Point-of-Care Testing
Figure 21: Global Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 22: Future Potential of NGS in Infectious Disease Diagnostics
Figure 23: Number of Molecular Diagnostics Patents for Infectious Diseases (by Year)
Figure 24: Number of Molecular Diagnostic Patents for Infectious Diseases (by Country/Organization)
Figure 25: Key Benefits of Home-Based Testing
Figure 26: Typical Supply Chain for a Diagnostic Test
Figure 27: Global Emerging Infectious Disease Diagnostics Market, Impact Analysis
Figure 28: Fiscal Response to the COVID-19 Pandemic (% of GDP)
Figure 29: Advantages of Point-of-Care Tests in Molecular Diagnostics
Figure 30: Key Clinical Areas Demanding Commercial Availability of Syndromic Tests
Figure 31: Advantages of INAAT over PCR
Figure 32: Number of LAMP Publications on Public Databases, 2016-2022
Figure 33: Number of INAAT Publications on Public Databases, 2016-2022
Figure 34: Advantages of Digital PCR over Quantitative Real-Time PCR
Figure 35: Number of “Digital PCR” Publications on Public Databases, 2016-2022
Figure 36: Notable Outbreaks of Infectious Diseases in Humans (by Region)
Figure 37: Number of Infectious Disease Outbreaks per Year Reported by the WHO, Global Estimates
Figure 38: Global Emerging Infectious Disease Diagnostics Market (by Application)
Figure 39: Global Emerging Infectious Disease Diagnostics Market (by Application), Share (%), 2022 and 2033
Figure 40: Global Emerging Infectious Disease Diagnostics Market (Laboratory Testing), $Billion, 2022-2033
Figure 41: Global Emerging Infectious Disease Diagnostics Market (Point-of-Care Testing), $Billion, 2022-2033
Figure 42: Global Emerging Infectious Disease Diagnostics Market (by Technology)
Figure 43: Global Emerging Infectious Disease Diagnostics Market (by Technology), Share (%), 2022 and 2033
Figure 44: Global Emerging Infectious Disease Diagnostics Market (PCR), $Billion, 2022-2033
Figure 45: Global Emerging Infectious Disease Diagnostics Market (RT-PCR), $Billion, 2022-2033
Figure 46: Global Emerging Infectious Disease Diagnostics Market (Digital PCR), $Billion, 2022-2033
Figure 47: Global Emerging Infectious Disease Diagnostics Market (Immunodiagnostics), $Billion, 2022-2033
Figure 48: Global Emerging Infectious Disease Diagnostics Market (Isothermal Nucleic Acid Amplification Technology (INAAT)), $Billion, 2022-2033
Figure 49: Global Emerging Infectious Disease Diagnostics Market (Next-Generation Sequencing (NGS)), $Billion, 2022-2033
Figure 50: Global Emerging Infectious Disease Diagnostics Market (Other Technologies), $Billion, 2022-2033
Figure 51: Global Emerging Infectious Disease Diagnostics Market (by Type of Infection)
Figure 52: Global Emerging Infectious Disease Diagnostics Market (by Type of Infection), Share (%), 2022 and 2033
Figure 53: Global Emerging Infectious Disease Diagnostics Market (Bacterial), $Billion, 2022-2033
Figure 54: Global Emerging Infectious Disease Diagnostics Market (Viral), $Billion, 2022-2033
Figure 55: Global Emerging Infectious Disease Diagnostics Market (Fungal), $Billion, 2022-2033
Figure 56: Global Emerging Infectious Disease Diagnostics Market (Other Infections), $Billion, 2022-2033
Figure 57: Global Emerging Infectious Disease Diagnostics Market (by Disease Type)
Figure 58: Global Emerging Infectious Disease Diagnostics Market (by Disease Type), Share (%), 2022 and 2033
Figure 59: Global Emerging Infectious Disease Diagnostics Market (Respiratory Infections), $Billion, 2022-2033
Figure 60: Global Emerging Infectious Disease Diagnostics Market (Gastrointestinal Infections), $Billion, 2022-2033
Figure 61: Global Emerging Infectious Disease Diagnostics Market (Sexually Transmitted Infections (STIs)), $Billion, 2022-2033
Figure 62: Global Emerging Infectious Disease Diagnostics Market (Other Infections), $Billion, 2022-2033
Figure 63: Global Emerging Infectious Disease Diagnostics Market (by End User)
Figure 64: Global Emerging Infectious Disease Diagnostics Market (by End User), Share (%), 2022 and 2033
Figure 65: Global Emerging Infectious Disease Diagnostics Market (Hospitals and Clinics), $Billion, 2022-2033
Figure 66: Global Emerging Infectious Disease Diagnostics Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 67: Global Emerging Infectious Disease Diagnostics Market (Other End Users), $Billion, 2022-2033
Figure 68: North America Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 69: North America Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 70: North America Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 71: North America Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 72: North America Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 73: North America Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 74: North America Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 75: U.S. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 76: U.S. Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 77: Canada Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 78: Canada Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 79: Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 80: Europe Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 81: Europe Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 82: Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 83: Europe Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 84: Europe Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 85: Europe Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 86: Germany Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 87: Germany Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 88: U.K. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 89: U.K. Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 90: France Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 91: France Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 92: Italy Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 93: Italy Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 94: Spain Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 95: Spain Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 96: Rest-of-Europe Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 97: Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 98: Asia-Pacific Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 99: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 100: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 101: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 102: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 103: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 104: Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 105: Japan Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 106: Japan Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 107: China Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 108: China Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 109: Australia Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 110: Australia Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 111: South Korea Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 112: South Korea Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 113: India Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 114: India Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 115: Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 116: Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 117: Latin America Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 118: Latin America Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 119: Latin America Emerging Infectious Disease Diagnostics Market (by Technology), $Million, 2022-2033
Figure 120: Latin America Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Million, 2022-2033
Figure 121: Latin America Emerging Infectious Disease Diagnostics Market (by Disease Type), $Million, 2022-2033
Figure 122: Latin America Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 123: Latin America Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 124: Brazil Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 125: Brazil Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 126: Mexico Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 127: Mexico Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 128: Rest-of-Latin America Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 129: Rest-of-Latin America Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 130: Middle East and Africa Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 131: Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Application), $Billion, 2022-2033
Figure 132: Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Technology), $Billion, 2022-2033
Figure 133: Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Billion, 2022-2033
Figure 134: Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Disease Type), $Billion, 2022-2033
Figure 135: Middle East and Africa Emerging Infectious Disease Diagnostics Market (by End User), $Billion, 2022-2033
Figure 136: Middle East and Africa Emerging Infectious Disease Diagnostics Market (by Country), % Share, 2022 and 2033
Figure 137: U.A.E. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 138: U.A.E. Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 139: K.S.A. Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 140: K.S.A. Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 141: Rest-of-Middle East and Africa Emerging Infectious Disease Diagnostics Market, $Billion, 2022-2033
Figure 142: Rest-of-Middle East and Africa Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2022-2033
Figure 143: Share of Key Developments, January 2019-June 2023
Figure 144: Number of Mergers and Acquisitions (by Company), January 2019-June 2023
Figure 145: Share of Synergistic Activities (by Company), January 2019-June 2023
Figure 146: Number of Business Expansions and Funding Activities (by Company), January 2019-June 2023
Figure 147: Number of Product Launches/Upgradations/Approvals (by Company), January 2019-June 2023
Figure 148: Market Share Analysis for Global Emerging Infectious Disease Diagnostics Market (by Company), 2022
Figure 149: Global Emerging Infectious Disease Diagnostics Market, Total Number of Companies Profiled
Figure 150: Abbott Laboratories: Product Portfolio
Figure 151: Abbott Laboratories: Overall Financials, $Million, 2020-2022
Figure 152: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
Figure 153: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
Figure 154: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
Figure 155: Becton, Dickinson and Company (BD): Product Portfolio
Figure 156: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
Figure 157: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
Figure 158: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
Figure 159: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
Figure 160: bioMérieux S.A.: Product Portfolio
Figure 161: bioMérieux S.A.: Overall Financials, $Million, 2020-2022
Figure 162: bioMérieux S.A.: Revenue (by Segment), $Million, 2020-2022
Figure 163: bioMérieux S.A.: Revenue (by Region), $Million, 2020-2022
Figure 164: bioMérieux S.A.: R&D Expenditure, $Million, 2020-2022
Figure 165: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 166: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 167: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 168: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 169: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 170: Co-Diagnostics, Inc.: Product Portfolio
Figure 171: DANAHER CORPORATION: Product Portfolio
Figure 172: DANAHER CORPORATION: Overall Financials, $Million, 2020-2022
Figure 173: DANAHER CORPORATION: Revenue (by Segment), $Million, 2020-2022
Figure 174: DANAHER CORPORATION: Revenue (by Region), $Million, 2020-2022
Figure 175: DANAHER CORPORATION: R&D Expenditure, $Million, 2020-2022
Figure 176: DiaSorin S.p.A.: Product Portfolio
Figure 177: DiaSorin S.p.A.: Overall Financials, $Million, 2021-2022
Figure 178: DiaSorin S.p.A.: Revenue (by Region), $Million, 2021-2022
Figure 179: DiaSorin S.p.A.: R&D Expenditure, $Million, 2021-2022
Figure 180: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 181: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 182: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 183: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 184: Hologic, Inc.: Product Portfolio
Figure 185: Hologic, Inc.: Overall Financials, $Million, 2020-2022
Figure 186: Hologic, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 187: Hologic, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 188: Hologic, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 189: QIAGEN N.V.: Product Portfolio
Figure 190: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
Figure 191: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
Figure 192: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
Figure 193: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
Figure 194: QuidelOrtho Corporation: Product Portfolio
Figure 195: QuidelOrtho Corporation: Overall Financials, $Million, 2020-2022
Figure 196: QuidelOrtho Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 197: QuidelOrtho Corporation: Revenue (by Region), $Million, 2020-2022
Figure 198: QuidelOrtho Corporation: R&D Expenditure, $Million, 2020-2022
Figure 199: T2 Biosystems, Inc.: Product Portfolio
Figure 200: Tecan Trading AG: Product Portfolio
Figure 201: Tecan Trading AG: Overall Financials, $Million, 2020-2022
Figure 202: Tecan Trading AG: Revenue (by Segment), $Million, 2020-2022
Figure 203: Tecan Trading AG: Revenue (by Region), $Million, 2020-2022
Figure 204: Tecan Trading AG: R&D Expenditure, $Million, 2020-2022
Figure 205: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 206: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 207: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 208: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 209: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022
Figure 210: Siemens Healthineers AG: Product Portfolio
Figure 211: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
Figure 212: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
Figure 213: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
Figure 214: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
Figure 215: CrisprBits: Overall Product Portfolio
Figure 216: Proof Diagnostics Inc.: Overall Product Portfolio
Figure 217: Evvy: Overall Product Portfolio
Figure 218: Sherlock Biosciences: Overall Product Portfolio
Figure 219: BioExcel Diagnostics: Overall Product Portfolio
Figure 220: En Carta Diagnostics: Overall Product Portfolio
Market Report Coverage
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The top segment players who are leading include manufacturers offering tests leveraging polymerase chain reaction (PCR) technology, which captured around 42.35% of the presence in the market in 2022. This was followed by immunodiagnostics at 30.75% market share in 2022.
Key Companies Profiled:
• Abbott Laboratories
• Becton, Dickinson and Company
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Co-Diagnostics, Inc.
• DANAHER CORPORATION
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• T2 Biosystems, Inc.
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The global emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Product launches, upgradations, and approvals accounted for the maximum number of key developments, i.e., over 70.00% of the total developments in the global emerging infectious disease diagnostics market, as of June 2023.
Competitive Strategy: The global emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the global emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.
Industry and Technology Overview
Introduction to Infectious Disease Diagnostics
The global emerging infectious disease diagnostics market was valued at $19.56 billion in 2022 and is expected to reach $37.21 billion by 2033, growing at a CAGR of 6.19% between 2023 and 2033. The key factors driving the growth of the global emerging infectious disease diagnostics market include the economic burden of infectious diseases, government support through funding and collaborations, increasing demand for point-of-care and syndromic testing, and technological advancements in molecular diagnostics.
Market Introduction
Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in accurate and timely disease diagnosis, enabling appropriate treatment decisions and public health interventions.
Microbiological culture is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.
Industrial Impact
Infectious disease diagnostics have a significant impact on various aspects of healthcare and public health. Here are some key impacts:
Accurate and Timely Diagnosis: Infectious disease diagnostics enable healthcare providers to accurately identify the causative agents of infections, leading to timely and appropriate treatment. Early diagnosis helps improve patient outcomes, reduce morbidity and mortality rates, and prevent the spread of infectious diseases.
Effective Patient Management: Diagnostic tests provide critical information for healthcare providers to guide patient management strategies. They help determine the most effective treatment options, including the selection of appropriate antimicrobial therapies and the implementation of infection control measures. This leads to better patient care and improved healthcare outcomes.
Public Health Surveillance and Outbreak Control: Infectious disease diagnostics play a crucial role in public health surveillance. By identifying and monitoring infectious agents, diagnostic tests contribute to the detection and tracking of disease outbreaks. This information helps public health authorities implement timely interventions, such as contact tracing, isolation measures, and targeted vaccination campaigns, to control the spread of infections.
Antimicrobial Stewardship: Accurate diagnostic tests help in the appropriate use of antimicrobial agents. By identifying the specific pathogens causing infections, healthcare providers can make informed decisions regarding antimicrobial prescriptions, avoiding unnecessary antibiotic use and reducing the risk of antimicrobial resistance.
Research and Development: Infectious disease diagnostics drive research and development efforts to improve existing diagnostic methods and develop new technologies. Ongoing advancements in diagnostics contribute to the discovery of novel biomarkers, the enhancement of diagnostic accuracy and sensitivity, and the integration of innovative approaches such as molecular techniques, biosensors, and artificial intelligence.
Impact of COVID-19
The COVID-19 pandemic has had a profound impact on infectious disease diagnostics globally. The urgent need for widespread testing to identify and control the spread of the virus has led to a rapid expansion of diagnostic capabilities. There has been an unprecedented surge in the development and deployment of diagnostic tests, including nucleic acid-based tests such as PCR and antigen tests, to detect SARS-CoV-2, the virus causing COVID-19. The pandemic has also accelerated advancements in point-of-care testing technologies, such as rapid antigen tests and molecular diagnostics, allowing for faster and more accessible testing.
Furthermore, the pandemic has highlighted the importance of surveillance systems, data sharing, and digital health technologies in monitoring and responding to infectious diseases. The lessons learned from COVID-19 are likely to have a long-lasting impact on the field of infectious disease diagnostics, driving innovations and improvements in testing capabilities, rapid response readiness, and global collaboration.
Market Segmentation:
Segmentation 1: by Application
• Laboratory Testing
• Point-of-Care Testing
Point-of-Care Testing to Register Significant Growth during the Forecast Period 2023-2033
Point-of-care (POC) testing for infectious diseases offers rapid and on-site diagnostic capabilities, enabling immediate detection and decision-making. POC tests are designed to be portable, user-friendly, and suitable for use in various healthcare settings. They provide quick results, often within minutes or hours, facilitating timely diagnosis and treatment decisions, particularly crucial for infectious diseases where early intervention can significantly impact patient outcomes and prevent further transmission.
POC tests are particularly useful in developing countries where there is a lack of robust laboratory infrastructure or high-end capital equipment to conduct diagnostic tests. They can help in the timely and accurate diagnosis of diseases in low-resource settings, thereby aiding in relieving the burden of infectious diseases in the region.
Segmentation 2: by Technology
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies
Next-Generation Sequencing (NGS) to Register Maximum Growth in the Market
Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.
Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).
• Digital PCR is an advanced molecular diagnostic technique used for infectious disease diagnostics. It enables the absolute quantification of target nucleic acids by partitioning the PCR reaction into thousands of individual reactions.
• INAAT has emerged as a valuable tool for infectious disease diagnostics. These techniques, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), enable rapid and sensitive detection of pathogens without the need for complex equipment or multiple temperature cycles.
• CRISPR is a relatively new technology, and while it has been leveraged for gene editing and therapeutic purposes ever since the invention of CRISPR/Cas9 gene editing in 2011, it was only in 2016 that CRISPR-Cas systems were first developed to identify nucleic acids for molecular diagnostics.
Segmentation 3: by Type of Infection
• Bacterial
• Viral
• Fungal
• Other Infections
Bacterial and Viral Infections to Dominate the Market
Bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.
Segmentation 4: by Disease Type
• Respiratory Infections
• Sexually Transmitted Infections (STIs)
• Gastrointestinal Infections
• Other Infections
Respiratory Infections to Dominate the Market Majorly Driven by the COVID-19 Pandemic
A vast majority of molecular diagnostic companies offer tests for testing various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as RT-PCR and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus at once in a single assay.
Segmentation 5: by End User
• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users
Hospitals and Clinics Continue to Dominate the Market
Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques like PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.
Segmentation 6: by Region
• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific - Japan, China, India, South Korea, Australia, Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, and Rest-of-Latin America
• Middle East and Africa - U.A.E., K.S.A., and Rest-of-Middle East and Africa
North America consists of the U.S. and Canada and accounts for the largest share of the global emerging infectious disease diagnostics market. The growth of the market in North America is driven largely by factors such as the presence of a large number of companies and the presence of robust laboratory infrastructure for conducting molecular diagnostic testing.
Recent Developments in the Emerging Infectious Disease Diagnostics Market
• In June 2023, T2 Biosystems announced a clinical collaboration with Vanderbilt University Medical Center to implement and evaluate the T2 bacteria panel for clinical use.
• In June 2023, T2 biosystems announced submission for FDA breakthrough device designation for its Candida Auris diagnostic test.
• In April 2023, Tecan Trading AG partnered with DYNEX Technologies to expand the availability of ELISA immunoassays in the U.S.
• In April 2023, QIAGEN N.V. introduced new syndromic testing solutions in Japan.
• In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.
• In February 2023, Sherlock Biosciences acquired Sense Biodetection, a molecular diagnostic company, to help advance the commercialization of its CRISPR-based diagnostic test.
• In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed round to support the development and commercialization of its CRISPR-based tests.
• In February 2023, FDA authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.
• In January 2023, CrisprBits developed India’s first CRISPR-based SARS-CoV-2 test with Omicron detection.
Demand – Drivers and Limitations
Market Demand Drivers:
Economic Burden of Infectious Diseases: Infectious diseases impose a significant economic burden on societies worldwide. The direct costs include expenses related to diagnosis, treatment, hospitalization, and healthcare utilization. Indirect costs arise from lost productivity due to illness, disability, or premature death. Furthermore, infectious disease outbreaks can disrupt trade, tourism, and supply chains, impacting sectors such as agriculture, manufacturing, and services.
Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases through Funding and Collaborations: Governments globally have been focused on allocating budgets and providing funding to advance research and early diagnosis in the field of infectious diseases.
Increasing Demand for Point-of-Care (POC) and Syndromic Testing: The demand for point-of-care testing is rising due to its advantages in delivering rapid results and facilitating immediate clinical decision-making. POCT allows for decentralized testing in various healthcare settings, including remote and resource-limited areas, enabling timely diagnosis and treatment initiation. This has driven the adoption of infectious disease diagnostics, particularly in areas with limited laboratory infrastructure.
Technological Advancements in Molecular Diagnostics: Advancements in diagnostic technologies have played a crucial role in the growth of the emerging infectious disease diagnostics market. These advancements include the development of molecular diagnostics, point-of-care testing, immunoassays, and automated systems, among others. These technologies provide rapid and accurate results, enabling healthcare professionals to make timely treatment decisions.
Market Challenges:
Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases: The overall gap between reimbursement and cost of point-of-care (POC) testing is increasing. Moreover, in the realm of technology-driven innovations, the endorsement of formal health technology assessments (HTAs) is frequently necessary to facilitate policy-level decisions regarding coverage, reimbursement, and utilization. However, the HTA process itself can be time-consuming and lead to delays in adoption decisions.
Erratic Trend in Infectious Disease Epidemic Outbreaks Globally: The emergence of infectious diseases is a consequence of the interactions between microbes and humans, which often involve complex and multifaceted factors. The erratic trend in the emergence/re-emergence of infectious disease outbreaks can make it very difficult to predict future outbreaks. Moreover, the mutating nature of causative agents such as viruses further complicates predicting the progression of an outbreak and its management.
Lack of an Established Framework for NGS-based Tests for Infectious Diseases: While tests have been made accessible under the EUA framework, the currently established frameworks for NGS-based tests are highly leaning toward oncology, making it inappropriate to be used as a reference for development and commercialization of tests for infectious diseases.
Market Opportunities:
Potential of Molecular Diagnostic Tests in Low-Resource Settings: While molecular diagnostics might not replace culture-based methods in the near future, they offer a significant advantage by providing access to testing for a vast number of individuals. This technology has the potential to revolutionize the surveillance of hard-to-reach populations and efficiently cover a large geographic area with limited resources.
Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance: Rapid diagnostic techniques play a crucial role in identifying newly emerging resistance traits, thereby promoting effective antibiotic stewardship. These techniques are invaluable in addressing two vital clinical questions, i.e., firstly, determining the necessity of antimicrobial therapy for a patient, and secondly, identifying the appropriate antimicrobial for successful treatment in the presence of microbial infection.
Analyst’s Thoughts
According to Prateeksha Singh, Lead Analyst - BIS Research, “With technological advancements in technologies such as digital PCR, isothermal nucleic acid amplification technologies, next-generation sequencing, and CRISPR-based diagnostics, the field of molecular diagnostics and point-of-care testing is expected to grow significantly in the next ten years.”
Emerging Infectious Disease Diagnostics Market - A Global and Regional Analysis
Focus on Application, Technology, Type of Infection, Disease Type, End User, and Country Analysis - Analysis and Forecast, 2023-2033
Frequently Asked Questions
Infectious diseases are illnesses caused by germs (such as bacteria, viruses, and fungi) that enter the body, multiply, and can cause an infection. Further, infectious disease diagnostics refers to the process of identifying and determining the presence of infectious agents, such as bacteria, viruses, fungi, or parasites, in a person's body. The goal of infectious disease diagnostics is to accurately detect and diagnose the specific pathogen responsible for an infection. This information is crucial for guiding appropriate treatment decisions and implementing necessary public health measures to control the spread of the disease.
Product launches, upgradations, and approvals accounted for the maximum number of key developments, i.e., over 70% of the total developments in the global emerging infectious disease diagnostics market, as of June 2023.
The following are the USPs of this report:
• Impact of COVID-19
• Timeline of emerging infectious disease diagnostic technologies
• Advantages and limitations of emerging infectious disease diagnostic technologies
• Future potential of emerging infectious disease diagnostic technologies
• Patent analysis
• Pipeline analysis
• Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
• Region-level market segmentation by application, technology, type of infection, disease type, and end user
• Country-level market segmentation by end user
• Supply chain analysis
• Snapshots of six emerging companies
Molecular diagnostic companies, as well as startups looking to enter the infectious disease diagnostics space, should buy this report.